Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study

Nocturia impairs quality of life (QoL). We have performed a non-interventional study in which men with lower urinary tract symptoms (LUTS) were treated for at least 3 months with tamsulosin oral controlled absorption system (0.4 mg q.d.). Other than observing efficacy and tolerability of this drug f...

Full description

Bibliographic Details
Main Authors: Martin C. Michel, Helmut Schumacher, Ludwig Mehlburger, Jean J.M.C.H. de la Rosette
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphar.2020.00816/full
id doaj-65c6f4a598e64122ab11ca4b987c8e1c
record_format Article
spelling doaj-65c6f4a598e64122ab11ca4b987c8e1c2020-11-25T03:22:05ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122020-06-011110.3389/fphar.2020.00816527516Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional StudyMartin C. Michel0Helmut Schumacher1Ludwig Mehlburger2Jean J.M.C.H. de la Rosette3Department of Pharmacology, Johannes Gutenberg University, Mainz, GermanyConsultant, Ingelheim, GermanyDepartment of Medical Affairs, Boehringer Ingelheim, Ingelheim, GermanyDepartment of Urology, Istanbul Medipol University, Istanbul, TurkeyNocturia impairs quality of life (QoL). We have performed a non-interventional study in which men with lower urinary tract symptoms (LUTS) were treated for at least 3 months with tamsulosin oral controlled absorption system (0.4 mg q.d.). Other than observing efficacy and tolerability of this drug formulation, the study was designed to explore the relative roles of number of nocturia episodes and of non-urological causes of nocturia on nocturia-related QoL at baseline and treatment-associated changes thereof. The study enrolled 5775 men seeking treatment of their LUTS. Tamsulosin improved LUTS, e.g. International Prostate Symptom Score from 19.5 ± 5.9 to 10.1 ± 4.9 (means ± SD). This was associated by clinically meaningful improvements in the Nocturia QoL score (from 45 ± 19 to 73 ± 17 points) and other QoL scores. Number of nocturnal voids was the key driver of all QoL scores at baseline; change of number of nocturia episodes that of improvement of all QoL scores upon treatment. In contrast, non-urological causes of nocturia such as heart failure, diabetes, sleep apnea, fluid or alcohol intake or use of diuretics or hypnotics had only small if any effects on baseline QoL or treatment-associated improvements thereof. The observed effects of non-urological causes on QoL apparently were largely driven by their effect on number of nocturnal voids. These data further support the idea that improvement of nocturia may be an important treatment goal in male LUTS.https://www.frontiersin.org/article/10.3389/fphar.2020.00816/fullmale lower urinary tract symptomsnocturiaquality of lifediabetesheart failure
collection DOAJ
language English
format Article
sources DOAJ
author Martin C. Michel
Helmut Schumacher
Ludwig Mehlburger
Jean J.M.C.H. de la Rosette
spellingShingle Martin C. Michel
Helmut Schumacher
Ludwig Mehlburger
Jean J.M.C.H. de la Rosette
Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study
Frontiers in Pharmacology
male lower urinary tract symptoms
nocturia
quality of life
diabetes
heart failure
author_facet Martin C. Michel
Helmut Schumacher
Ludwig Mehlburger
Jean J.M.C.H. de la Rosette
author_sort Martin C. Michel
title Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study
title_short Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study
title_full Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study
title_fullStr Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study
title_full_unstemmed Factors Associated With Nocturia-Related Quality of Life in Men With Lower Urinary Tract Symptoms and Treated With Tamsulosin Oral Controlled Absorption System in a Non-Interventional Study
title_sort factors associated with nocturia-related quality of life in men with lower urinary tract symptoms and treated with tamsulosin oral controlled absorption system in a non-interventional study
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2020-06-01
description Nocturia impairs quality of life (QoL). We have performed a non-interventional study in which men with lower urinary tract symptoms (LUTS) were treated for at least 3 months with tamsulosin oral controlled absorption system (0.4 mg q.d.). Other than observing efficacy and tolerability of this drug formulation, the study was designed to explore the relative roles of number of nocturia episodes and of non-urological causes of nocturia on nocturia-related QoL at baseline and treatment-associated changes thereof. The study enrolled 5775 men seeking treatment of their LUTS. Tamsulosin improved LUTS, e.g. International Prostate Symptom Score from 19.5 ± 5.9 to 10.1 ± 4.9 (means ± SD). This was associated by clinically meaningful improvements in the Nocturia QoL score (from 45 ± 19 to 73 ± 17 points) and other QoL scores. Number of nocturnal voids was the key driver of all QoL scores at baseline; change of number of nocturia episodes that of improvement of all QoL scores upon treatment. In contrast, non-urological causes of nocturia such as heart failure, diabetes, sleep apnea, fluid or alcohol intake or use of diuretics or hypnotics had only small if any effects on baseline QoL or treatment-associated improvements thereof. The observed effects of non-urological causes on QoL apparently were largely driven by their effect on number of nocturnal voids. These data further support the idea that improvement of nocturia may be an important treatment goal in male LUTS.
topic male lower urinary tract symptoms
nocturia
quality of life
diabetes
heart failure
url https://www.frontiersin.org/article/10.3389/fphar.2020.00816/full
work_keys_str_mv AT martincmichel factorsassociatedwithnocturiarelatedqualityoflifeinmenwithlowerurinarytractsymptomsandtreatedwithtamsulosinoralcontrolledabsorptionsysteminanoninterventionalstudy
AT helmutschumacher factorsassociatedwithnocturiarelatedqualityoflifeinmenwithlowerurinarytractsymptomsandtreatedwithtamsulosinoralcontrolledabsorptionsysteminanoninterventionalstudy
AT ludwigmehlburger factorsassociatedwithnocturiarelatedqualityoflifeinmenwithlowerurinarytractsymptomsandtreatedwithtamsulosinoralcontrolledabsorptionsysteminanoninterventionalstudy
AT jeanjmchdelarosette factorsassociatedwithnocturiarelatedqualityoflifeinmenwithlowerurinarytractsymptomsandtreatedwithtamsulosinoralcontrolledabsorptionsysteminanoninterventionalstudy
_version_ 1724611286100082688